[Cannabis] GW Pharma Reports Preliminary Q4 Revenue Of $108M, 'Exceptional' Launch Year For Epidiolex

Browse By

GW Pharmaceuticals plc (NASDAQ: GWPHissued preliminary unaudited fourth-quarter financial results Sunday that show total net product sales of around $108 million.

The company posted preliminary net sales of $309 million for the full year ended Dec. 3.

Net Epidiolex sales were projected to have hit about $104 million in the fourth quarter and $296 million in 2019 as a whole. 

GW Pharma said it plans to post official fourth-quarter and full-year 2019 financial results Feb. 25. 

Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily …

Full story available on Benzinga.com

Source Benzinga

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.